tiprankstipranks
Trending News
More News >

Lucid Diagnostics price target raised to $7.75 from $7.50 at Ascendiant

Ascendiant raised the firm’s price target on Lucid Diagnostics (LUCD) to $7.75 from $7.50 and keeps a Buy rating on the shares following the Q1 report. The firm says expected high growth in 2025 should drive the stock “much higher.”

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1